|
The changes during 2008 were as follows:
| |
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of January 1, 2008:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of December 31, 2008:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Other intangible assets in 2008 consist of:
The estimated amortization expense for these other intangible assets for each of the five succeeding years are:
The expected weighted average remaining life of other intangible assets is 11.1 years as of December 31, 2008.
The additions acquired through business combinations in 2008 consist of the acquired intangible assets of Respironics of EUR
1,186 million, Genlyte of EUR 860 million, and VISICU of EUR 33 million. The acquired intangible assets mainly consist of
customer relationships and patents of Respironics of EUR 732 million and Genlyte EUR 614 million, and core technology of Respironics
of EUR 355 million and VISICU of EUR 20 million.
The unamortized costs of computer software to be sold, leased or otherwise marketed amounted to EUR 95 million (2007: EUR
63 million). The amounts charged to the income statement for amortization or impairment of these capitalized computer software
costs amounted to EUR 33 million (2007: EUR 20 million).
|
